利拉鲁肽对 2 型糖尿病患者的高密度脂蛋白载脂蛋白 AI 动力学无影响

IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Laurence Duvillard , Jean-Paul Pais de Barros , Alexia Rouland , Isabelle Simoneau , Damien Denimal , Benjamin Bouillet , Jean-Michel Petit , Bruno Vergès
{"title":"利拉鲁肽对 2 型糖尿病患者的高密度脂蛋白载脂蛋白 AI 动力学无影响","authors":"Laurence Duvillard ,&nbsp;Jean-Paul Pais de Barros ,&nbsp;Alexia Rouland ,&nbsp;Isabelle Simoneau ,&nbsp;Damien Denimal ,&nbsp;Benjamin Bouillet ,&nbsp;Jean-Michel Petit ,&nbsp;Bruno Vergès","doi":"10.1016/j.diabet.2024.101535","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>The catabolism of high density lipoprotein (HDL) apolipoprotein AI (apoAI) is accelerated in patients with type 2 diabetes (T2D), related to hypertriglyceridemia, insulin resistance and low plasma adiponectin levels. Since liraglutide is likely to partly correct these abnormalities, we hypothesized that it might have a beneficial effect on HDL apoAI kinetics in patients with T2D.</p></div><div><h3>Methods</h3><p>An <em>in vivo</em> kinetic study of HDL apoAI was performed in 10 patients with T2D before and after 6 months of treatment with 1.2 mg/day of liraglutide, using a bolus of l-[1–<sup>13</sup>C]leucine followed by a 16-hour constant infusion.</p></div><div><h3>Results</h3><p>Liraglutide reduced BMI (34.9 ± 4.7 <em>vs</em> 36.6 ± 4.9 kg/m<sup>2</sup>, <em>P</em> = 0.012), HbA1c (7.1 ± 1.1 <em>vs</em> 9.6 ± 2.6%, <em>P</em> = 0.003), HOMA-IR (5.5 ± 1.9 <em>vs</em> 11.6 ± 11.2, <em>P</em> = 0.003), fasting triglycerides (1.76 ± 0.37 <em>vs</em> 2.48 ± 0.69 mmol/l, <em>P</em> &lt; 0.001) and triglycerides during kinetics (2.34 ± 0.81 <em>vs</em> 2.66 ± 0.65 mmol/l, <em>P</em> = 0.053). Plasma HDL cholesterol and adiponectin concentrations were unchanged (respectively 0.97 ± 0.26 <em>vs</em> 0.97 ± 0.19 mmol/l, <em>P</em> = 1; 3169 ± 1561 <em>vs</em> 2618 ± 1651 µg/l, <em>P</em> = 0.160), similar to triglyceride content in HDL (5.13 ± 1.73 vs 5.39 ± 1.07%, <em>P</em> = 0.386). Liraglutide modified neither HDL apoAI fractional catabolic rate (0.35 ± 0.11 vs 0.38 ± 0.11 pool/day, <em>P</em> = 0.375), nor its production rate (0.44 ± 0.13 vs 0.49 ± 0.15 g/l/day, <em>P</em> = 0.375), nor its plasma concentration (1.26 ± 0.19 vs 1.29 ± 0.14 g/l, <em>P</em> = 0.386).</p></div><div><h3>Conclusion</h3><p>Six months of treatment with 1.2 mg/day of liraglutide had no effect on the kinetics of HDL apoAI in patients with T2D. The lack of decrease in triglyceride content in HDL related to an only moderate decrease in triglyceridemia, probably greatly explains these results. Insufficient improvement of insulin sensitivity and adiponectinemia may also be implied.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"50 3","pages":"Article 101535"},"PeriodicalIF":4.6000,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1262363624000272/pdfft?md5=919dc39fbfcf1c9138f9637d0e35003d&pid=1-s2.0-S1262363624000272-main.pdf","citationCount":"0","resultStr":"{\"title\":\"No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes\",\"authors\":\"Laurence Duvillard ,&nbsp;Jean-Paul Pais de Barros ,&nbsp;Alexia Rouland ,&nbsp;Isabelle Simoneau ,&nbsp;Damien Denimal ,&nbsp;Benjamin Bouillet ,&nbsp;Jean-Michel Petit ,&nbsp;Bruno Vergès\",\"doi\":\"10.1016/j.diabet.2024.101535\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aim</h3><p>The catabolism of high density lipoprotein (HDL) apolipoprotein AI (apoAI) is accelerated in patients with type 2 diabetes (T2D), related to hypertriglyceridemia, insulin resistance and low plasma adiponectin levels. Since liraglutide is likely to partly correct these abnormalities, we hypothesized that it might have a beneficial effect on HDL apoAI kinetics in patients with T2D.</p></div><div><h3>Methods</h3><p>An <em>in vivo</em> kinetic study of HDL apoAI was performed in 10 patients with T2D before and after 6 months of treatment with 1.2 mg/day of liraglutide, using a bolus of l-[1–<sup>13</sup>C]leucine followed by a 16-hour constant infusion.</p></div><div><h3>Results</h3><p>Liraglutide reduced BMI (34.9 ± 4.7 <em>vs</em> 36.6 ± 4.9 kg/m<sup>2</sup>, <em>P</em> = 0.012), HbA1c (7.1 ± 1.1 <em>vs</em> 9.6 ± 2.6%, <em>P</em> = 0.003), HOMA-IR (5.5 ± 1.9 <em>vs</em> 11.6 ± 11.2, <em>P</em> = 0.003), fasting triglycerides (1.76 ± 0.37 <em>vs</em> 2.48 ± 0.69 mmol/l, <em>P</em> &lt; 0.001) and triglycerides during kinetics (2.34 ± 0.81 <em>vs</em> 2.66 ± 0.65 mmol/l, <em>P</em> = 0.053). Plasma HDL cholesterol and adiponectin concentrations were unchanged (respectively 0.97 ± 0.26 <em>vs</em> 0.97 ± 0.19 mmol/l, <em>P</em> = 1; 3169 ± 1561 <em>vs</em> 2618 ± 1651 µg/l, <em>P</em> = 0.160), similar to triglyceride content in HDL (5.13 ± 1.73 vs 5.39 ± 1.07%, <em>P</em> = 0.386). Liraglutide modified neither HDL apoAI fractional catabolic rate (0.35 ± 0.11 vs 0.38 ± 0.11 pool/day, <em>P</em> = 0.375), nor its production rate (0.44 ± 0.13 vs 0.49 ± 0.15 g/l/day, <em>P</em> = 0.375), nor its plasma concentration (1.26 ± 0.19 vs 1.29 ± 0.14 g/l, <em>P</em> = 0.386).</p></div><div><h3>Conclusion</h3><p>Six months of treatment with 1.2 mg/day of liraglutide had no effect on the kinetics of HDL apoAI in patients with T2D. The lack of decrease in triglyceride content in HDL related to an only moderate decrease in triglyceridemia, probably greatly explains these results. Insufficient improvement of insulin sensitivity and adiponectinemia may also be implied.</p></div>\",\"PeriodicalId\":11334,\"journal\":{\"name\":\"Diabetes & metabolism\",\"volume\":\"50 3\",\"pages\":\"Article 101535\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1262363624000272/pdfft?md5=919dc39fbfcf1c9138f9637d0e35003d&pid=1-s2.0-S1262363624000272-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes & metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1262363624000272\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363624000272","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目的2型糖尿病(T2D)患者体内高密度脂蛋白(HDL)载脂蛋白AI(apoAI)的分解代谢加快,这与高甘油三酯血症、胰岛素抵抗和血浆脂联素水平低有关。由于利拉鲁肽可能会部分纠正这些异常,我们假设它可能会对 T2D 患者的高密度脂蛋白载脂蛋白A动力学产生有益的影响。方法对 10 名 T2D 患者进行了高密度脂蛋白载脂蛋白A动力学研究,在使用 1.2 毫克/天的利拉鲁肽治疗 6 个月之前和之后,使用 l-[1-13C]leucine 注射液,然后进行 16 小时的持续输注。结果 利拉鲁肽降低了体重指数(34.9 ± 4.7 vs 36.6 ± 4.9 kg/m2,P = 0.012)、HbA1c(7.1 ± 1.1 vs 9.6 ± 2.6%,P = 0.003)、HOMA-IR(5.5 ± 1.9 vs 11.6 ± 11.2,P = 0.003)、空腹甘油三酯(1.76 ± 0.37 vs 2.48 ± 0.69 mmol/l,P < 0.001)和动力学过程中的甘油三酯(2.34 ± 0.81 vs 2.66 ± 0.65 mmol/l,P = 0.053)。血浆高密度脂蛋白胆固醇和脂联素的浓度没有变化(分别为 0.97 ± 0.26 vs 0.97 ± 0.19 mmol/l,P = 1;3169 ± 1561 vs 2618 ± 1651 µg/l,P = 0.160),与高密度脂蛋白中甘油三酯的含量相似(5.13 ± 1.73 vs 5.39 ± 1.07%,P = 0.386)。利拉鲁肽既不改变高密度脂蛋白载脂蛋白的分解率(0.35 ± 0.11 vs 0.38 ± 0.11 池/天,P = 0.375),也不改变其生成率(0.44 ± 0.13 vs 0.49 ± 0.15 克/升/天,P = 0.结论1.2 毫克/天的利拉鲁肽治疗 6 个月对 T2D 患者高密度脂蛋白 apoAI 的动力学没有影响。高密度脂蛋白中甘油三酯含量的下降与甘油三酯血症的适度下降无关,这可能在很大程度上解释了上述结果。胰岛素敏感性和脂联素血症改善不足也可能是原因之一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
No effect of liraglutide on high density lipoprotein apolipoprotein AI kinetics in patients with type 2 diabetes

Aim

The catabolism of high density lipoprotein (HDL) apolipoprotein AI (apoAI) is accelerated in patients with type 2 diabetes (T2D), related to hypertriglyceridemia, insulin resistance and low plasma adiponectin levels. Since liraglutide is likely to partly correct these abnormalities, we hypothesized that it might have a beneficial effect on HDL apoAI kinetics in patients with T2D.

Methods

An in vivo kinetic study of HDL apoAI was performed in 10 patients with T2D before and after 6 months of treatment with 1.2 mg/day of liraglutide, using a bolus of l-[1–13C]leucine followed by a 16-hour constant infusion.

Results

Liraglutide reduced BMI (34.9 ± 4.7 vs 36.6 ± 4.9 kg/m2, P = 0.012), HbA1c (7.1 ± 1.1 vs 9.6 ± 2.6%, P = 0.003), HOMA-IR (5.5 ± 1.9 vs 11.6 ± 11.2, P = 0.003), fasting triglycerides (1.76 ± 0.37 vs 2.48 ± 0.69 mmol/l, P < 0.001) and triglycerides during kinetics (2.34 ± 0.81 vs 2.66 ± 0.65 mmol/l, P = 0.053). Plasma HDL cholesterol and adiponectin concentrations were unchanged (respectively 0.97 ± 0.26 vs 0.97 ± 0.19 mmol/l, P = 1; 3169 ± 1561 vs 2618 ± 1651 µg/l, P = 0.160), similar to triglyceride content in HDL (5.13 ± 1.73 vs 5.39 ± 1.07%, P = 0.386). Liraglutide modified neither HDL apoAI fractional catabolic rate (0.35 ± 0.11 vs 0.38 ± 0.11 pool/day, P = 0.375), nor its production rate (0.44 ± 0.13 vs 0.49 ± 0.15 g/l/day, P = 0.375), nor its plasma concentration (1.26 ± 0.19 vs 1.29 ± 0.14 g/l, P = 0.386).

Conclusion

Six months of treatment with 1.2 mg/day of liraglutide had no effect on the kinetics of HDL apoAI in patients with T2D. The lack of decrease in triglyceride content in HDL related to an only moderate decrease in triglyceridemia, probably greatly explains these results. Insufficient improvement of insulin sensitivity and adiponectinemia may also be implied.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes & metabolism
Diabetes & metabolism 医学-内分泌学与代谢
CiteScore
12.00
自引率
4.20%
发文量
86
审稿时长
13 days
期刊介绍: A high quality scientific journal with an international readership Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing. Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信